Note 12 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2024

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Purchase Commitments

We contract with various third parties to conduct certain activities including clinical operations and contract manufacturing, and for the clinical and commercial supply of BRIUMVI. Certain contracts contain non-cancellable features or require us to make binding forecasts for future purchases. As of December 31, 2024 the Company had aggregate non-cancelable purchase commitments of $214.7 million, of which $64.2 million, $74.4 million and $76.1 million are expected to be incurred in the years 2025, 2026 and 2027, respectively. These amounts do not represent the Company's entire anticipated purchases in the future as the amounts of such obligations are dependent on the timing of future orders, and the terms of the agreement, which we believe at this time cannot be reasonably estimated.

Loan Payable

See Note 7 – for a detail description of our loan agreement.

Leases

See Note 8 - for a detailed description of our lease arrangements in New York, New Jersey and North Carolina.